The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst like Keay Nakae from Chardan Capital could instill confidence among investors and potentially lead to a positive short-term impact on Avidity Biosciences' stock price. Analyst ratings often influence investor perception and can lead to price movements.